IL5 and asthma: Briegel et al. [94] hypothesized that the combined blockage of the two pathways might result in optimal disease control in severe asthma patients, for those where an anti-IL-5 or anti-IL-5R treatment alone is insufficient, as well as in patients in which symptomatic hypereosinophilia occurs under Dupilumab treatment.